Company

RyCarma Therapeutics

Biotechnology Research Manager Jobs 8 employees

Employees: 8
Contacts: 3
Emails: 3
Phones: 2

www.rycarma.com LinkedIn

RyCarma Therapeutics Overview

Headquarters: Manager Jobs
Website: www.rycarma.com
Industry: Biotechnology Research
Employees: 8
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

on ryanodine receptors (RyRs)

About RyCarma Therapeutics

RyCarma is a clinical-stage biotech company developing first-in-class small molecule therapeutics for cardiovascular and skeletal muscle diseases. Our drug discovery platform is built from deep expertise on ryanodine receptors (RyRs), channels that regulate the intracellular flow of calcium ions in nearly all cell types. We hold an exclusive license from Columbia University for its RyR technology based on the research of our founder, Dr. Andrew Marks. RyCarma’s lead candidate, ARM210, is in development for the treatment of heart failure and ryanodine receptor 1-related myopathies (RYR1-RM).

RyCarma Therapeutics Contact Details

People in AeroLeads: 4
With contact data: 3
Email contacts: 3; 75.0% coverage
Phone contacts: 2; 50.0% coverage

RyCarma Therapeutics Org Chart

Sample employees and titles

Name	Title	Location	Contact
Garrett Skolkin	Student in the Vagelos Molecular Life		View
Chloe Ibsen	Associate Director, Corporate	Boston, Massachusetts, United States	Email Phone
Elizabeth Tarka	Adjunct Faculty Associate Professor	Phoenixville, Pennsylvania, United States	Email Phone
Dr. Dmitrij Hristodorov	General Partner at Forbion	Munich, Bavaria, Germany	Email